Atricure, Inc. · NASDAQ:ATRC
Atricure — Q2 2026 Earnings Presentation
24 slides from Atricure's earnings presentation, July 2026
Slide 1: Creating a World Class Platform: Investor Presentation
Creating a World Class Platform Investor Presentation July 2026 © 2026 AtriCure, Inc. All rights reserved.
Slide 2: Forward Looking Statements and Non-GAAP Financial Measures
Forward Looking Statements and Non-GAAP Financial Measures This presentation and oral statements made in connection with this presentation contain “forward-looking statements,” which are statements related to future events that by their nature address matters that are uncertain. Forward-looking stat
Slide 3: Our Vision: Establishing AtriCure as the Standard of Care
Our Vision Establishing AtriCure as the Standard of Care Strong Portfolio Existing products and solutions and continuous We are innovation driving consistent, profitable growth passionately Large and Growing Markets focused on Addressing underserved and growing patient populations, representing over
Slide 4: Afib: A Serious Problem
Afib: A Serious Problem Afib affects more than 59 million people worldwide. It is estimated that 45% have suffered more than a year from Afib. 5x Higher Risk of >5x Higher Risk of Stroke Heart Failure 46% Greater Risk of >3x Higher Risk of Mortality Dementia © 2026 AtriCure, Inc. All rights reserved
Slide 5: A Persistent Pain Problem
A Persistent Pain Problem Pain after surgery slows recovery. Pain after surgery increases healthcare costs. Pain after surgery reduces quality of life. 30%-50% of patients report persistent pain lasting months to years post-surgery 1 in 7 thoracotomy patients 1 in 11 minimally invasive develop an op
Slide 6: Evolution of Our Global Market Opportunity
Evolution of Our Global Market Opportunity Leading with Innovation, Clinical Science and Awareness to establish and grow our markets $1B $5B+ $10B+ Current Global Market 2010 Markets Opportunity by 2030 Market opportunity and penetration estimates based on internal estimates and research, as well as
Slide 7: Establishing AtriCure as the Standard of Care
Establishing AtriCure as the Standard of Care Cardiac Surgery Pain Management Hybrid Therapies Globally, all Cardiac Cryo Nerve Block Increase treatment of Our Vision for Surgery patients benefit reduces pain, minimizes LS Persistent Afib Standard from ablation + AtriClip narcotic use, and patients
Slide 8: Establishing AtriCure as the Standard of Care: Cardiac Surgery
Establishing AtriCure as the Standard of Care Cardiac Surgery Globally, all Cardiac ISOLATOR® SYNERGY Our Vision for Surgery patients benefit ENCOMPASS ® CLAMP Standard from ablation + AtriClip to reduce Afib and of Care strokes. ~$7B+ Estimated Total Market Nearly 2 million patients annually Opport
Slide 9: Treatment of Afib and LAAM: Advancing Guidelines
Treatment of Afib and LAAM Advancing Guidelines for Clinical Practice Lasts beyond 7 days Lasts longer than 1 year and as long as 1 year without stopping Sources included in Appendix © 2026 AtriCure, Inc. All rights reserved. 9
Slide 10: Treatment of Afib and LAAM: Improving Access through Reimbursement
Treatment of Afib and LAAM Improving Access through Reimbursement Hospital Reimbursement MS-DRG 317 Hospital Reimbursement Epicardial Ablation + MS-DRG 212 Lasts longer than 1 year Physician Reimbursement Epicardial LAA CPT 33267, 33268, 33269 AVR + MVR + Surgical without stopping Ablation $15k - $2
Slide 11: BoxX-NoAF Overview
BoxX-NoAF Overview Box Lesion Creation with LAA EXclusion to Prevent New-onset Atrial Fibrillation in Cardiac Surgery Patients Highlights & Study Rationale IDE Trial to demonstrate that left atrial concomitant ablation and left atrial • POAF is the most common complication appendage exclusion during
Slide 12: LeAAPS Overview
Le ft LeAAPS Overview Atrial CLINICAL TRIAL Appendage Exclusion for P rophylactic S troke Reduction IDE Trial to evaluate the effectiveness of prophylactic LAA exclusion Highlights for prevention of ischemic stroke or systemic arterial embolism in • Seminal clinical trial – one of the cardiac surger
Slide 13: Establishing AtriCure as the Standard of Care: Pain Management
Establishing AtriCure as the Standard of Care Pain Management Cryo Nerve Block Our Vision for reduces pain, minimizes Standard narcotic use, and of Care improves recovery time in surgical procedures. 60 Seconds to Manage Post-Operative Pain with cryoSPHERE MAX ~$2B Estimated Total Market Nearly 1 mi
Slide 14: Pain Management: A Decade of Progress
Pain Management Post-Operative pain was a problem we identified and leveraged our history of addressing unmet clinical needs + A Decade of Progress ablation expertise to cultivate new markets. Cryo Nerve Block for Amputations is the next opportunity. 2015 CRYO2 510(k) clearance for pain management M
Slide 15: Future Built from Innovation and Operational Excellence
Future Built from Innovation and Operational Excellence 2025 Performance and 2026 Outlook outpacing our long-term goals $1B Annual Revenue 2030 ~$750M+ Annual Revenue 2028 $535M 20%+ Adjusted EBITDA Margin 2025 Annual Revenue ~14% Adjusted EBITDA Margin 14.9% 75%+ FCF conversion 2025 Revenue Growth
Slide 16: Milestones Supporting Our Vision
Milestones Supporting Our Vision 2024–2025 2026–2027 2028 and beyond • AtriClip Pro-Mini • Next gen EnCompass • cryoXT launch • cryoXT Probe • BoxX-NoAF PMA – POAF • BoxX-NoAF enrollment • LeAAPS fully enrolled indication • BoxX-NoAF data • Initiate BoxX-NoAF • LeAAPS data and PMA – • First In-Human
Slide 17: Financial Results and 2026 Outlook
Financial Results and 2026 Outlook ($ Millions) Significant Investment in Growth Catalysts $650 while Expanding Operating Leverage $600 +13% $550 2026 Guidance $500 +15% $450 Worldwide Revenue +17% $400 $602 million to $610 million +21% Approximately 13-14% YoY growth $350 $300 +20% Adjusted EBITDA
Slide 18: Second Quarter 2026 Financial Highlights
Second Quarter 2026 Financial Highlights Worldwide Revenue* ($ Millions) $153.6 Key Metrics* +12.8% YoY Q2 2026 Q2 2025 WORLDWIDE REVENUE $153.6M $136.1M $141.2 GROSS MARGIN 77.2% 74.5% OPERATING EXPENSES $109.0M $107.7M $136.1 ADJUSTED EBITDA+ $27.3M $15.4M NET INCOME (LOSS) $9.0M ($6.2M) CASH & IN
Slide 19: Distinct Opportunity for Value Creation As We Execute Our Vision
Distinct Opportunity for Value Creation As We Execute Our Vision Robust, #1 Leader in organic R&D each market. pipeline. Unrivaled commitment to Broad Innovation and develop and support our Clinical Science initiatives partners and patients. across platforms. Vastly Driving underpenetrated profitabl
Slide 20: Thank You!
Thank You! © 2026 AtriCure, Inc. All rights reserved.
Slide 21: Key Products
Key Products ISOLATOR® SYNERGY ATRICLIP ENCOMPASS ® CLAMP FLEX•MiniTM DEVICE ATRICLIP ® FLEX・V ® DEVICE cryoSPHERE ® MAX PROBE cryoSPHERE ® CRYOABLATION PROBE cryoXT® DEVICE EPI-SENSE ® DEVICE ISOLATOR® SYNERGY CLAMP ATRICLIP PRO・V® DEVICE © 2026 AtriCure, Inc. All rights reserved. 21
Slide 22: Innovation and Clinical Milestones
Innovation and Clinical Milestones 2010+ 2015+ 2020+ • Synergy system FDA • EPi-Sense® system • EPi-Sense approved by FDA for approved for treatment of acquired treatment of long-standing persistent Afib Afib concomitant to open heart procedures • AtriClip PRO-V® • EnCompass® clamp • AtriClip® devic
Slide 23: References
References Page Metric Reference 4 59 million people with Afib Worldwide Linz, D., Gawalko, M., Betz, K., Hendriks, J. M., Lip, G. Y., Vinter, N., Guo, Y. & Johnsen, S. (2024). Atrial fibrillation: epidemiology, screening and digital health. The Lancet Regional Health–Europe, Volume 37, 100786, Febr
Slide 24: Sources Tables Abbreviations
Sources Tables Abbreviations Treatment of Afib and LAAM Advancing Guidelines for Clinical Practice Key Abbreviations Sources: January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland Jr, J. C., ... & Yancy, C. W. Afib or AF Atrial Fibrillation (2019). 2019 AHA/ACC/HRS focuse